These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27782226)

  • 21. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed for the treatment of non-small cell lung cancer.
    Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The changing scenario of 1
    Russo A; Franchina T; Ricciardi GRR; Toscano G; Schifano S; Lo Certo G; Battaglia A; Pantò E; Scaffidi Fonti M; Adamo V
    Crit Rev Oncol Hematol; 2018 Oct; 130():1-12. PubMed ID: 30196906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
    Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
    Walzer S; Chouaid C; Lister J; Gultyaev D; Vergnenegre A; de Marinis F; Meng J; de Castro Carpeno J; Crott R; Kleman M; Ngoh C
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):121-8. PubMed ID: 25248391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.
    Stinchcombe TE; Borghaei H; Barker SS; Treat JA; Obasaju C
    Clin Lung Cancer; 2016 Jan; 17(1):1-9. PubMed ID: 26340853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving role of histology in the management of advanced non-small-cell lung cancer.
    Langer CJ; Besse B; Gualberto A; Brambilla E; Soria JC
    J Clin Oncol; 2010 Dec; 28(36):5311-20. PubMed ID: 21079145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
    Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
    Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatments for advanced stage non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.